antiphospholipid syndrome
Information
- Disease name
- antiphospholipid syndrome
- Disease ID
- DOID:2988
- Description
- "An autoimmune disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin)." [url:http\://en.wikipedia.org/wiki/Antiphospholipid_syndrome, url:https\://www.genome.gov/Genetic-Disorders/Antiphospholipid-Syndrome] {comment="ls:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03684564 | Active, not recruiting | Phase 2 | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | July 9, 2021 | August 2025 |
| NCT00076713 | Completed | Antiphospholipid Syndrome Collaborative Registry (APSCORE) | April 2000 | April 2007 | |
| NCT00180817 | Completed | Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies. | September 1998 | August 31, 2005 | |
| NCT05313048 | Completed | Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination | March 15, 2022 | October 24, 2022 | |
| NCT05195372 | Completed | Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome | January 1, 2015 | July 2022 | |
| NCT00537290 | Completed | Phase 2 | A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome | September 2007 | January 2013 |
| NCT04153201 | Completed | N/A | Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome | January 15, 2013 | October 16, 2019 |
| NCT00674297 | Completed | Phase 2 | Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients | May 2008 | February 2013 |
| NCT00878137 | Completed | Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin | March 2009 | May 2009 | |
| NCT01104337 | Completed | Phase 4 | Drug Interaction Between Paracetamol and Warfarin | March 2007 | February 2010 |
| NCT03994302 | Completed | Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX) | June 1, 2019 | April 8, 2023 | |
| NCT01318057 | Completed | Pharmacogenetics of Warfarin in Puerto Ricans. | February 2011 | July 2014 | |
| NCT01475149 | Completed | Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) | September 2010 | August 2016 | |
| NCT03969498 | Completed | Evaluation of the Incidence of Cancer in the Follow-up of Women With 3 Consecutive Embryonic Demises Before 10 Weeks or 1 Fetal Death, According to Their Thrombophilia Status, With a Special Focus on Women With an Obstetric Antiphospholipid Symdrome (oAPS) | January 2, 2018 | December 31, 2018 | |
| NCT03893357 | Completed | Prevalence of Antiphospholipid Antibodies in the Hemodialysis Patients Population Within the CHU Brugmann Hospital | March 1, 2019 | July 25, 2019 | |
| NCT02855047 | Completed | The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations | July 2005 | March 2015 | |
| NCT02833194 | Completed | Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome | July 2005 | July 2015 | |
| NCT01660061 | Completed | Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome | July 2011 | December 2014 | |
| NCT03682419 | Completed | N/A | Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) | September 17, 2018 | November 23, 2018 |
| NCT03600636 | Completed | N/A | Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter | December 7, 2018 | February 29, 2020 |
| NCT03348306 | Completed | N/A | Multi-organ Screening for Asymptomatic Ischaemia in Antiphospholipid Syndrome | July 20, 2018 | January 14, 2022 |
| NCT02295475 | Completed | Phase 4 | Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome | December 10, 2014 | March 2022 |
| NCT02926170 | Completed | Phase 3 | Rivaroxaban for Patients With Antiphospholipid Syndrome | March 13, 2013 | December 31, 2017 |
| NCT02326051 | Completed | Phase 4 | Timing of Initiation of LMWH Administration in Pregnant Women With APS | December 2014 | May 2017 |
| NCT05583305 | Enrolling by invitation | Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome | October 12, 2022 | July 17, 2026 | |
| NCT06420154 | Not yet recruiting | Early Phase 1 | The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases | May 27, 2024 | May 27, 2027 |
| NCT05128760 | Not yet recruiting | Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study) | January 1, 2022 | December 1, 2024 | |
| NCT06379646 | Not yet recruiting | N/A | An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease | April 22, 2024 | April 21, 2026 |
| NCT05644210 | Recruiting | Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE | October 1, 2022 | December 30, 2025 | |
| NCT05859997 | Recruiting | N/A | Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases | May 17, 2023 | July 17, 2025 |
| NCT05983952 | Recruiting | Phase 2 | Anti-CD38 Antibody Treating APS With Thrombocytopenia | August 2023 | August 2025 |
| NCT05995600 | Recruiting | Phase 4 | Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE | February 20, 2024 | October 2028 |
| NCT06373003 | Recruiting | Negative Antiphospholipid Syndrome: a Multicentric Study | March 31, 2024 | March 31, 2026 | |
| NCT06373081 | Recruiting | N/A | Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease | April 20, 2024 | April 15, 2026 |
| NCT06373926 | Recruiting | N/A | Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome | March 28, 2023 | March 2025 |
| NCT05416190 | Recruiting | N/A | Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant | June 2, 2022 | December 2024 |
| NCT00198068 | Recruiting | Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) | September 2003 | March 2025 | |
| NCT05646394 | Recruiting | Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS | July 1, 2022 | December 31, 2027 | |
| NCT00616317 | Recruiting | Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study | September 2006 | January 2040 | |
| NCT04262492 | Recruiting | International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants | October 21, 2020 | April 2030 | |
| NCT04308564 | Recruiting | Laboratory and Clinical Data in Antiphospholipid Patients | April 12, 2021 | April 1, 2031 | |
| NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
| NCT03890601 | Recruiting | New Biological Tests in Patients With Antiphospholipid Antibodies | March 13, 2019 | March 13, 2027 | |
| NCT05020782 | Recruiting | Phase 2/Phase 3 | The BeLimumab Antiphospholipid Syndrome Trial (BLAST) | June 1, 2022 | January 1, 2025 |
| NCT02303171 | Recruiting | Phase 4 | Use of Warfarin After the First Trimester in Pregnant Women With APS | November 2014 | June 2025 |
| NCT00482794 | Recruiting | Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome | June 2006 | December 2024 | |
| NCT05199909 | Recruiting | Phase 2 | Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia | January 25, 2022 | June 30, 2024 |
| NCT02450396 | Recruiting | Pregnancy and Medically Assisted Conception in Rare Diseases | June 2014 | December 2025 | |
| NCT02157272 | Terminated | Phase 3 | Rivaroxaban in Thrombotic Antiphospholipid Syndrome | December 2014 | January 25, 2018 |
| NCT01784523 | Terminated | Phase 3 | Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients | February 2013 | September 30, 2015 |
| NCT01649479 | Terminated | N/A | Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome | April 2013 | September 2013 |
| NCT03303508 | Unknown status | N/A | Measurement of Anti-dsDNA by Both CLIFT & ELISA | September 1, 2018 | October 1, 2019 |
| NCT03384485 | Unknown status | N/A | Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome. | February 1, 2018 | October 1, 2018 |
| NCT01818505 | Unknown status | The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome | March 2013 | ||
| NCT01538134 | Unknown status | Antiphospholipid Antibodies and Fetal Growth Restriction | June 2015 | March 2016 | |
| NCT01538121 | Unknown status | Antiphospholipid Antibodies and Early Severe Preeclampsia. | June 2015 | August 2016 | |
| NCT01151644 | Unknown status | Phase 4 | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | April 2010 | December 2010 |
| NCT04624269 | Unknown status | Phase 4 | A Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Spontaneous Abortion With Antiphospholipid Syndrome | December 1, 2020 | February 1, 2023 |
| NCT00278616 | Withdrawn | Phase 1 | Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome | August 2005 | October 2011 |
| NCT00180778 | Withdrawn | Phase 1/Phase 2 | Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss | October 2005 | October 2005 |
- Disase is a (Disease Ontology)
- DOID:417
- Cross Reference ID (Disease Ontology)
- GARD:5824
- Cross Reference ID (Disease Ontology)
- ICD10CM:D68.61
- Cross Reference ID (Disease Ontology)
- MESH:D016736
- Cross Reference ID (Disease Ontology)
- MIM:107320
- Cross Reference ID (Disease Ontology)
- NCI:C61283
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:201450008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0085278
- Exact Synonym (Disease Ontology)
- antiphospholipid antibody syndrome
- Exact Synonym (Disease Ontology)
- APS
- MedGen concept unique identifier (MedGen Concept name)
- C0085278
- MedGen unique identifier (MedGen Concept name)
- 38834
- MeSH unique ID (MeSH (Medical Subject Headings))
- D016736